Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

iBio, Inc. IBIO

Healthcare  —  Biotechnology
1.19 (0.01) (0.83%) as of 25 Sep
Market cap
$77.3M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

iBio, Inc. (IBIO) Business Profile

Updated before January 2025

Company Overview

iBio, Inc. (IBIO) is a biotechnology company that specializes in plant-based biologics manufacturing and development. Founded in 2008, iBio is headquartered in Bryan, Texas, and operates with a mission to revolutionize the biopharmaceutical industry by leveraging its proprietary plant-based technology platform. The company was initially established as a spin-off from the Fraunhofer USA Center for Molecular Biotechnology. Over the years, iBio has gained recognition for its innovative approach to biologics production, which offers a faster, more scalable, and cost-effective alternative to traditional methods.

Key leadership at iBio includes Tom Isett, who serves as the Chairman and Chief Executive Officer. Under his leadership, the company has focused on expanding its capabilities in biologics manufacturing, therapeutic development, and vaccine production. The leadership team also includes experienced professionals in biotechnology, finance, and operations, ensuring a well-rounded approach to achieving the company’s strategic goals.

Core Business Segments

Biologics Contract Development and Manufacturing Organization (CDMO) Services

iBio offers CDMO services that leverage its proprietary FastPharming® System, a plant-based expression platform. This system enables the rapid production of biologics, including monoclonal antibodies, vaccines, and other therapeutic proteins. Key services under this segment include:

  • Process Development: Custom development of biologics manufacturing processes tailored to client needs.
  • cGMP Manufacturing: Production of clinical and commercial-grade biologics in compliance with current Good Manufacturing Practices (cGMP).
  • Analytical Services: Comprehensive testing and quality assurance for biologics.

Therapeutics and Vaccines

iBio is actively involved in the development of its own pipeline of therapeutics and vaccines. The company focuses on addressing unmet medical needs in areas such as oncology, infectious diseases, and fibrotic diseases. Notable products and programs include:

  • IBIO-100: A lead therapeutic candidate targeting fibrotic diseases.
  • COVID-19 Vaccine Development: Leveraging the FastPharming® System to develop vaccine candidates for COVID-19.

Research and Development (R&D)

The R&D segment is a cornerstone of iBio’s business, driving innovation in biologics production and therapeutic development. The company invests heavily in advancing its FastPharming® technology and exploring new applications for plant-based biologics.

Business Model

iBio’s business model is built on a combination of service-based revenue from its CDMO operations and product-based revenue from its proprietary therapeutics and vaccines. The FastPharming® System serves as the backbone of the company’s operations, enabling rapid and cost-effective biologics production. By offering CDMO services, iBio generates steady revenue while simultaneously advancing its own pipeline of products. This dual approach allows the company to balance short-term profitability with long-term growth potential.

Additionally, iBio’s plant-based technology provides a competitive edge by reducing production timelines and costs compared to traditional mammalian cell-based systems. This unique value proposition attracts clients from various sectors, including pharmaceuticals, biotechnology, and government agencies.

Strategic Direction

iBio is focused on several strategic initiatives to drive future growth:

  • Pipeline Expansion: The company aims to advance its existing therapeutic candidates while exploring new indications and product categories.
  • CDMO Growth: iBio plans to expand its CDMO services by enhancing its manufacturing capabilities and attracting more clients.
  • Sustainability Goals: Leveraging plant-based technology aligns with global sustainability trends, as it reduces the environmental impact of biologics production.
  • Global Partnerships: iBio seeks to establish strategic partnerships and collaborations to accelerate product development and expand its market reach.

Competitive Landscape

iBio operates in a highly competitive biotechnology industry. Key competitors include:

  • Catalent, Inc.: A leading provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.
  • Lonza Group: A global leader in biologics manufacturing and development services.
  • Emergent BioSolutions: Specializes in the development and manufacturing of vaccines and therapeutics.
  • Medicago: A direct competitor in plant-based biologics production.

Despite the competition, iBio differentiates itself through its proprietary FastPharming® System, which offers unique advantages in speed, scalability, and cost-effectiveness.

Risk Factors

iBio faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its CDMO services and proprietary products.
  • Supply Chain Disruptions: Dependence on raw materials and third-party suppliers poses a risk of delays or shortages.
  • Regulatory Challenges: Compliance with stringent regulatory requirements for biologics manufacturing and approval can be time-consuming and costly.
  • Competition: The biotechnology industry is highly competitive, with larger players having more resources and established market presence.
  • Financial Risks: As a smaller company, iBio may face challenges in securing funding for its R&D and operational needs.

Recent Developments

In recent years, iBio has made significant strides in advancing its technology and product pipeline. Key developments include:

  • COVID-19 Vaccine Candidates: iBio utilized its FastPharming® System to develop vaccine candidates for COVID-19, demonstrating the platform’s versatility and speed.
  • Partnerships: The company has entered into collaborations with academic institutions and industry partners to enhance its R&D capabilities.
  • Facility Expansion: iBio has invested in upgrading its manufacturing facilities to support increased demand for its CDMO services.

Global developments, such as the COVID-19 pandemic, have highlighted the importance of rapid biologics production, positioning iBio as a key player in addressing future public health challenges.

Investment Considerations

Strengths

  • Innovative Technology: The FastPharming® System offers a unique competitive advantage in biologics production.
  • Dual Revenue Streams: iBio’s combination of CDMO services and proprietary products provides a balanced business model.
  • Growth Potential: The company’s focus on expanding its pipeline and CDMO services positions it for long-term growth.
  • Sustainability: Plant-based biologics production aligns with global sustainability trends.

Risks

  • Financial Stability: As a smaller company, iBio may face challenges in maintaining financial stability.
  • Regulatory Hurdles: Compliance with regulatory requirements can delay product development and approval.
  • Market Competition: Larger competitors with more resources may pose a threat to iBio’s market share.

Conclusion

iBio, Inc. is a pioneering biotechnology company with a strong focus on plant-based biologics production. Its innovative FastPharming® System, combined with a dual revenue model, positions the company as a key player in the biopharmaceutical industry. While iBio faces challenges such as competition and regulatory hurdles, its strategic initiatives and growth potential make it an attractive option for investors seeking exposure to the biotechnology sector. With a commitment to innovation and sustainability, iBio is well-positioned to capitalize on emerging opportunities and drive future growth.